Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors

This study has been terminated.
(Accrual Goal Met)
Sponsor:
Collaborator:
Indiana University
Information provided by:
Indiana University
ClinicalTrials.gov Identifier:
NCT00198172
First received: September 8, 2005
Last updated: May 30, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2007
  Estimated Primary Completion Date: No date given